Characteristics of studies included.
| Study | Country of Study | Sample Size | No. of Joints | No. of Assessors | Blinding | Reliabilitya | TJC | SJC |
|---|---|---|---|---|---|---|---|---|
| Heegaard, 201316* | Denmark | 31 | 28 | 1 | Y | Both | Y | Y |
| El Miedany, 201017* | UK | 82 | 28 | U | U | Both | Y | N |
| Levy, 200718* | US | 60 | 28 | 1 | Y | Inter | Y | Y |
| Wong, 199919* | Worldwide | 60 | · Mannequin: 50 TJCs, 48 SJCs | |||||
| · Text: 20 TJCs, 18 SJCs | U | Y | Inter | Y | Y | |||
| Hanly, 199620* | Canada | 61 | 20 | 4 | Y | Inter | Y | Y |
| Prevoo (Site 1), 199621* | Netherlands | 141 | 28 | U | U | Inter | Y | Y |
| Prevoo (Site 2), 199621* | Netherlands | 101 | 28 | U | U | Inter | Y | Y |
| Abraham, 199322* | US | 32 | 50 clinician; 42 patient | 1 | Y | Inter | Y | N |
| Radner, 201211 | Austria | 209 | 28 | 3 | Y | Inter | Y | Y |
| Janta, 201312 | Spain | 102 | 28 | 1 | Y | Inter | Y | Y |
| Amaya-Amaya, 201223 | Colombia | 135 | 28 | U | Y | Inter | Y | Y |
| Cheung, 201024 | France | 50 | 28 | 2 | Y | Inter | Y | Y |
| Figueroa, 200725* | US | 82 | 58 clinician; 60 patient | 3 | U | Inter | Y | Y |
| Kavanaugh, 201013 | US | 447 | 28 | U | Y | Inter | Y | Y |
| Riazzoli, 201026* | Sweden | 47 | 28 | 1 | U | Inter | Y | Y |
| El Miedany and Palmer, 200827 | UK | 148 | 28 | U | U | Inter | Y | N |
| Alarcón, 199914 | US | 67 | 36 | 1 | Y | Inter | Y | N |
| Calvo, 199928* | Peru | 60 | 36 | 1 | U | Inter | Y | N |
| Greenwood, 200629* | UK | 45 | 28 | 1 | U | Inter | Y | Y |
| Inderjeeth, 201930* | Australia | 52 | 28 | U | Y | Inter | Y | Y |
| Houssien, 199931* | UK | 100 | 28 | 1 | Y | Inter | Y | Y |